# Effect of Bronchipret on Antiviral Immune Response in Patients With Mild COVID-19

> **NCT05276375** · PHASE2 · COMPLETED · sponsor: **Dr. Frank Behrens** · enrollment: 21 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Bronchipret

## Key facts

- **NCT ID:** NCT05276375
- **Lead sponsor:** Dr. Frank Behrens
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-14
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05276375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05276375, "Effect of Bronchipret on Antiviral Immune Response in Patients With Mild COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05276375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*